Enhancement of the vasodepressor response to adenosine by nicorandil in rats: Comparison with cromakalim

Fundamental and Clinical Pharmacology

Volumn 12, Issue 1, 1998, Pages 37-43

  Saito, K ^a   Sakai, K ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cromakalim; K(ATP) channel activation; Nicorandil; Potentiation of adenosine induced vasodepression; Rats

Indexed keywords

ADENOSINE; CROMAKALIM; GLIBENCLAMIDE; NICORANDIL; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031881912     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00921.x     Document Type: Article

References (29)

1. Aversuno T, Ouyang P, Silverman, H. Blockade of the ATP-sensitive potassium channel modulates reactive hyperemia in the canine coronary circulation. Circ Res 1991 ; 69 : 618-22
2. Bache RJ, Dymek DJ. Local and regional regulation of coronary vascular tone. Prog Cardiovasc Dis 1981 ; 24 : 191-212
3. Belloni FL, Hintze TH. Glihenclamide attenuates adenosine-induced bradycardia and coronary vasodilatation. Am J Physiol 1991 ; 261 : H720-7
4. + channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin -I-contracted arterial preparations. Comparison to aprikalim (RP 52891) and nitroglycerin. J Pharmacol Exp Ther 1991 ; 259 : 526-34
5. Cavero I, Mondot S, Mestre M. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels. J Pharmacol Exp Ther 1989 ; 248 : 1261-8
6. Clapham JC, Hamilton TC, Longman SD, Buckingham RE, Campbell CA. Antihypertensive and haemodynamic properties of the potassium channel activating (-)enantiomer of cromakalim in animal models. Arzneim-Forsch/Drug Res 1991 ; 41 : 385-91
7. Cushing DJ, Brown GL, Sabouni MH, Mustafa SJ. Adenosine receptor-mediated coronary artery relaxation and cyclic nucleotide production. Am J Physiol 1991 ; 261 : H343-8
8. Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen L. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990; 247 : 1341-4
9. Drury AN, Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol (Lond) 1929 ; 68 : 213-37
10. + channels responsible for adenosine A, receptor-mediated vasodepression does not involve a pertussis toxin-sensitive G protein. Eur J Pharmacol 1993 ; 236 : 255-62
11. Ghaleh B, Dubois-Rande J-L, Hittinger L, Giudicelli J-F, Bordeaux A. Comparison of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium. Br J Pharmacol 1995 ; 114 : 496-502
12. Hamilton TC, Weston AH. Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol 1989 ; 20 : 1-9
13. Imagawa J, Akima M, Nabata H, Taira N. Spasmolytic action of nicorandil in canine conductive coronary arteries in vivo is not modified by glibenclamide. J Cardiovasc Pharmacol 1992 ; 19 : 108-14
14. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990 ; 4 : 1075-88
15. Krumenacker M, Roland E. Clinical profile of nicorandil: an overview of its haemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992 ; 20 : S93-102
16. Kukovetz WR, Holzmann S. Cyclic GMP in nicorandil-induced vasodilatation and tolerance development. J Cardiovasc Pharmacol 1987 ; 10 : S25-30
17. a) receptors. J Pharmacol Exp Ther 1983 ; 227: 316-21
18. Mubagwa K, Mullane K, Flaming W. Role of adenosine in the heart and circulation. Cardiovasc Res 1996 ; 32 : 797-813
19. + Channels in Cardiovascular Medicine. France: Springer Verlag, 1993 : 95-106
20. + channels in the sustained coronary vasodilator response to adenosine in dogs. Eur J Pharmacol 1993 ; 231 : 185-9
21. Rubino A, Burnstock G. Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Cardiovasc Res 1996 ; 31 : 469-79
22. Sakai K, Nakano H, Nagano H, Uchida Y. Nicorandil. In: Scriabine A, ed. New Drugs Annual: Cardiovascular Drugs. New York: Raven Press, 1983 : 227-42
23. Sakai K. Nicorandil: animal pharmacology. Am J Cardiol 1989 ; 63: 2J-10
24. Shiraki Y, Akima M, Nabata H, Ohba Y, Hoshino E, Sakai K. The hyportensive mechanisms of the new anti-anginal drug, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75) in beagle dogs. Jpn J Pharmacol 1981 ; 31 : 921-9
25. + channels in arterial smooth muscle. Science 1989 ; 245 : 177-80
26. Suryapranata H. The cardiovascular profile of nicorandil. Rev Contemp Pharmacother 1993 ; 4 : 207-14
27. Taira N, Satoh K, Yanagisawa T, Imai Y, Hiwatari M. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidethyl nitrate (SG-75). Clin Exp Pharmacol Physiol 1979 ; 6 : 301-16
28. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989 ; 63 : 18J-24
29. Yanagisawa T. Taira N. Effect of 2-nicotinamidethyl nitrate (SG-75) on the membrane potential of left atrial muscle fibres of the dog. Increase in potassium conductance. Naunyn Schmiedebergs Arch Pharmacol 1980 ; 312 : 69-76